FDA told London-based Confer With that its Vivant True Tone skin-lightening serum is an unapproved drug sold without FDA approval.
What happened
FDA reviewed product labeling on Confer With's own website and on the Vivant Skin Care website (no plant inspection was made). The labeling promotes the serum for hyperpigmentation, melasma, dark spots and age spots and names hydroquinone (2%) as an ingredient, which FDA treats as evidence the product is a drug. Because FDA proposed in 2006 that over-the-counter skin bleaching drugs are not generally recognized as safe and effective, the product is an unapproved new drug and is misbranded.
What FDA found
Labeling on the company's website and the Vivant Skin Care site claims the serum treats hyperpigmentation, melasma and dark spots, which makes it a drug under the law.
Section 201(g)(1)(B) and (C) of the FD&C Act, 21 U.S.C. 321(g)(1)(B)-(C); 21 CFR 201.128OTC skin bleaching products, including those with hydroquinone, were proposed by FDA in 2006 as not generally recognized as safe and effective, so this product falls under the OTC drug rules that require an approved application.
Section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4); 71 FR 51146 (August 29, 2006)No FDA-approved new drug application is in effect for the product, so selling it is an unapproved new drug violation.
Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)Because it is an unapproved nonprescription drug that does not meet section 505G, the product is misbranded.
Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)Shipping a misbranded or unapproved drug across state lines, or delivering it for shipping, is prohibited.
Sections 301(a) and 301(d) of the FD&C Act, 21 U.S.C. 331(a), 331(d)
What FDA wants
FDA asks the company to write back within 15 working days explaining what it has done to fix the violations and prevent them from happening again, or to explain any delay and give a completion schedule if it cannot finish in time. If the company believes the product is not in violation, it should send its reasoning and supporting information.
Who should pay attention
- retailers and online marketplaces that list skin-lightening serums
- brands selling hydroquinone-containing cosmetic or drug products in the US
- US importers and distributors of UK skincare brands
This is a summary. Read the original letter on fda.gov.